Last reviewed · How we verify
HBV-6
HBV-6, marketed by the Beijing Center for Disease Control and Prevention, is a small molecule drug with an undisclosed mechanism of action, currently holding a position in the market without specified primary indication or revenue data. The key strength of HBV-6 lies in its current market availability, with the protection of a key composition patent expiring in 2028. The primary risk is the lack of detailed clinical trial results and clear identification of competitors, which may impact its long-term market sustainability.
At a glance
| Generic name | HBV-6 |
|---|---|
| Sponsor | Beijing Center for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers (PHASE4)
- The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBV-6 CI brief — competitive landscape report
- HBV-6 updates RSS · CI watch RSS
- Beijing Center for Disease Control and Prevention portfolio CI